News
October
19
2021
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
Read more
October
07
2021
BioWorld Today
The team at BioWorld wrote a detailed article on our Phase 2/3 RT001 study readout, highlighting the statistically significant survival benefits of treatment as compared to control.
Read more
October
06
2021
Endpoints News
Endpoints News published an extensive article on the results of our Phase 2/3 study of RT001 in patients with INAD. The article offers great context for the study data, as well as our plans for pursuing a potential regulatory approval pathway for the treatment in this ultra-rare disease with no current treatment options.
Read more
October
06
2021
FierceBiotech
A roundup article on the data readout from our Phase 2/3 RT001 study in INAD was published by FierceBiotech. The piece does an excellent job summarizing the study results and discussing the next steps.
Read more
October
06
2021
Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)
Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)
Read more
August
11
2021
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
Read more
May
07
2021
ALS News Today
Check out this article from ALS News Today on Retrotope's rapid enrollment of its ongoing Phase 2 trial of RT001 for the treatment of amyotrophic lateral sclerosis (ALS). The piece offers great context on the ongoing study, as well as how the mechanism of action for RT001 may be able to help patients with neurodegenerative diseases such as ALS.
Read more
March
22
2021
TRICALS
We appreciate TRICALS helping raise awareness of the initiation of our Phase 2 clinical study of RT001 in ALS in Europe. A special thank you to the world-class clinical investigators who are making this trial possible.
Read more
March
05
2021
American Academy of Ophthalmology: Week in Review
News of Retrotope's recent rare pediatric disease designation for RT001 in INAD was included in AAO's "Week in Review" roundup of key ophthalmic news. Did you know Retrotope also has a preclinical program in dry AMD? An IND filing for RT011 in this indication is expected in 2021.
Read more
March
04
2021
Friedreich’s Ataxia News
The team at Friedreich’s Ataxia News helped spread the word about Retrotope's recent rare pediatric disease designation and Fast Track designation for RT001 in FA. Our pivotal Phase 2/3 trial of RT001 in FA is fully enrolled and we expect data from the study by the end of 2021.
Read more
February
16
2021
Retrotope’s presentation at 2021 BIO CEO & Investor Digital Conference, by Anil Kumar
Anil Kumar, Retrotope’s president and chief business officer, gave a corporate presentation as part of the 2021 BIO CEO & Investor Digital Conference. The presentation highlighted a busy year ahead for Retrotope with multiple key data readouts planned for its broad clinical-stage pipeline.
Read more
February
01
2021
The Concept of the LPO in Lipid Membranes
A matchstick animation illustrating the concept of the LPO in lipid membranes, and the role of D-PUFAs in inhibiting the chain reaction.
Read more
April
21
2020
Video about Retrotope’s Friedreich’s ataxia study
Dr. Mark Midei, Retrotope's Chief of Medical Affairs, and Susan Walther, Director of Patient Engagement at Friedreich's Ataxia Research Alliance (FARA), recorded a video about Retrotope’s Friedreich’s ataxia study.
Read more
May
17
2019
Charles Cantor – GoldLab Symposium 2019
Dr. Charles Cantor, co-founder and executive director of Retrotope, Inc., presenting on GoldLab Symposium 2019.
Read more
March
31
2019
Mikhail Shchepinov presenting at Undoing Aging 2019
Mikhail Shchepinov, Chief Scientific Officer at Retrotope, Inc., presenting at Undoing Aging 2019 in Berlin.
Read more
March
13
2019
EMA Grants Orphan Medicinal Product Designation for Retrotope RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)